Lactandrate exhibits growth inhibitory effects on breast cancer cells (GI50 values ranging from 5 to 65 μM); demonstrates antitumor activity in mouse mammary tumors (MXT and CD8F1) and human MX-1 xenograft models; interacts with the ligand-binding domain (LBD) of estrogen receptor-alpha (ERα).